Clinical Study on Treatment of Juvenile Myelomonocytic Leukemia with Haploidentical-Hematopoietic Stem Cell Transplantation.
- Author:
Li DING
1
;
Heng ZHU
2
;
Dong-Mei HAN
1
;
Zhi-Dong WANG
1
;
Xiao-Li ZHENG
1
;
Lei DONG
1
;
Hong-Min YAN
1
;
Jing LIU
1
;
Ling ZHU
1
;
Mei XUE
1
;
Zi-Kuan GUO
3
;
Heng-Xiang WANG
4
Author Information
- Publication Type:Journal Article
- From: Journal of Experimental Hematology 2017;25(5):1524-1527
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo analyze the therapeutic efficacy of haploidentical-hematopoietic stem cell transplantation (hi-HSCT) for patients with juvenile myelomonocytic leukemia (JMML).
METHODSThe engraftment of hematopoietic stem cells, incidence of graft versus host disease (GVHD), infection, relapse, and survival of 6 JMML patients received hi-HSCT were retrospectively analyzed.
RESULTSSix (6 males) JMML patients received hi-HSCT from haplo-HLA-matched related donors. The results showed that the hematopoictic stem cells in all 6 patients were grafted successfully. Two cases of JMML died of pulmenary infections, other 4 cases survive without disease. Acute GVHD occurred in 3 patients and chronic GVHD occurred in 1 patients. The overall survival, disease free survival and relapse rates were 66.7%, 66.7%, 0%, respectively.
CONCLUSIONThe hi-HSCT is an effective method for treatment of patients with JMML, but there also is a serial problems to be resolved.
